retatrutide glp-1 for weight loss: Study shows 30% body weight loss Retatrutide vs Tirzepatide Compared |

Transcranial administration of the connexin hemichannel inhibitor CBX, but not the pannexin hemichannel inhibitor probenecid (image not shown), prevented the formation of jellyfish and honeycomb microglia (green) relative to vehicle-treated mice after compression injury

Why it matters: The GLP-1 market remains driven by weight loss efficacy

Patients were randomly assigned to orforglipron (12 mg or 36 mg) or semaglutide (7 mg or 14 mg) with a treatment period of 52 weeks, from 22 September 2022 to 22 August 2025, and drugs were administered orally once per day

Changes in size or color, or border irregularity must be viewed with suspicion